読み込み中
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新データ
$36.295
+$11.095 · +44.03%
Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.
通常取引
$36.30
+$11.10 · +44.05%
日中の時刻はETです。市場データは遅延する場合があります。
Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.
日中レンジ
現在 $36.30
52週レンジ
現在 $36.30
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
54
適正価値
センチメント
71
強気
リスク
20
低リスク
モメンタム
53
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.
日中レンジ
現在 $36.30
52週レンジ
現在 $36.30
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 7.26億 USD | 7.01億 USD | 6.75億 USD | 6.67億 USD | 5.42億 USD |
| 売上原価 | 1.5億 USD | 1.7億 USD | 1.85億 USD | 1.99億 USD | 1.4億 USD |
| 粗利益 | 5.77億 USD | 5.31億 USD | 4.9億 USD | 4.68億 USD | 4.01億 USD |
| 研究開発 | 1.17億 USD | 8157.7万 USD | 7625.7万 USD | 8479.7万 USD | 5554.5万 USD |
| 販売・一般管理 | 3.69億 USD | 2.94億 USD | 2.69億 USD | 2.55億 USD | 1.99億 USD |
| 営業費用 | 5.43億 USD | 6.04億 USD | 4.03億 USD | 4.08億 USD | 3.11億 USD |
| 受取利息 | 2273.2万 USD | 1968.9万 USD | 1144.4万 USD | 454.2万 USD | 89.6万 USD |
| 支払利息 | 1460.6万 USD | 1656.9万 USD | 1731万 USD | 3557.6万 USD | 2899.6万 USD |
| 減価償却費と償却費 | 9102.3万 USD | 7878.5万 USD | 7557.4万 USD | 9150.1万 USD | 2854.8万 USD |
| 営業利益 | 3330.3万 USD | −7337.1万 USD | 8767.5万 USD | 6002.4万 USD | 8992.4万 USD |
| 純利益 | 703.4万 USD | −9956万 USD | 4195.5万 USD | 1590.9万 USD | 4198万 USD |
会社概要が更新されました 2026年10月8日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$29.60
下落余地（18.46%）この株式へのエクスポージャーを報告している上場投資信託です。
iShares Core S&P Small-Cap ETFIJR6004.54万0.06%1042.94億 USD0.06%$136.41-0.49%
Vanguard Morningstar Total Stock Market ETFVTI3104.87万0.00%2.3兆 USD0.03%$380.32-0.19%
iShares Russell 2000 ETFIWM2616.78万0.03%785.63億 USD0.19%$275.81-0.68%
Avantis U.S. Small Cap Value ETFAVUV2278.35万0.07%305.4億 USD0.25%$119.19+0.05%
Vanguard Morningstar Small-Cap ETFVB2222.8万0.01%1853億 USD0.03%$285.95-0.36%
U.S. Small Cap Value Portfolio ETF Class SharesDFSV1987.69万0.07%266.88億 USD0.33%$37.785-0.03%
Vanguard Morningstar Small-Cap Value ETFVBR1414.23万0.02%682億 USD0.05%$231.68-0.21%
Vanguard Extended Market ETFVXF1188.25万0.01%954億 USD0.05%$232.36-0.49%iShares Core S&P Small-Cap ETFIJRVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMAvantis U.S. Small Cap Value ETFAVUVVanguard Morningstar Small-Cap ETFVBU.S. Small Cap Value Portfolio ETF Class SharesDFSVVanguard Morningstar Small-Cap Value ETFVBRVanguard Extended Market ETFVXFAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
